MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Ursofalk 250mg capsules (Dr. Falk Pharma UK Ltd).

Stability Notes

Powder is hygroscopic. Store in airtight container. Maximum 7 days in MCA.

Provenance

This compatibility recommendation is derived from Vancocin Matrigel 125mg capsules (Flynn Pharma Ltd).

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Destolit 150mg tablets (Norgine Pharmaceuticals Ltd).

Stability Notes

Store in airtight containers.

Provenance

This compatibility recommendation is derived from Valtrex 500mg tablets (GlaxoSmithKline UK Ltd) and Valaciclovir 500mg tablets (Ranbaxy (UK) Ltd).

Stability Notes

Store in an airtight container.

Provenance

This compatibility recommendation is derived from Co-Diovan 80mg/12.5mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

Store in an airtight container.

Provenance

This compatibility recommendation is derived from Co-Diovan 160mg/25mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

Store in an airtight container.

Provenance

This compatibility recommendation is derived from Co-Diovan 160mg/12.5mg tablets (Novartis Pharmaceuticals UK Ltd).

Stability Notes

Hygroscopic powder, therefore protect from moisture.

Provenance

This compatibility recommendation is derived from Valsartan 80mg capsules (Milpharm Ltd).

Stability Notes

Hygroscopic powder, therefore protect from moisture.

Provenance

This compatibility recommendation is derived from Valsartan 40mg capsules (Milpharm Ltd).

Stability Notes

Hygroscopic powder, therefore protect from moisture.

Provenance

This compatibility recommendation is derived from Valsartan 160mg capsules (Milpharm Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.